Summary by Moomoo AI
Ginkgo Bioworks Holdings, Inc. has completed its annual financial and operational performance review for the fiscal year ended December 31, 2023, as detailed in its Annual Report on Form 10-K. The company operates through two main segments: Cell Engineering, which generates revenue through R&D services, cell programming, and downstream value share such as milestones and royalties; and Biosecurity, which earns through biomonitoring and bioinformatic support services, though it saw a decrease in product revenue with the end of COVID-19 testing in schools. Ginkgo has formed strategic partnerships and holds equity positions in several ventures, applying equity method investments and fair value options for some. Despite reporting significant net losses, Ginkgo emphasizes its focus on long-term value. The company's stock...Show More